SHIP2 is a positive regulator in the PI3K signaling pathway, a cell-signaling pathway. SHIP2 is overexpressed in many breast cancer cell lines; inhibition of SHIP2 results in decreased cell growth and cell metastasis in those cell lines. Due to these characteristics, inhibitors of SHIP2 have been investigated for potential anti-cancer drugs. The aim of this study was to increase the affinity of the SHIP2 inhibitor and increase the specificity of the inhibitor by decreasing the affinity for the SHIP1 enzyme. Analogues of the parent compound, AS1949490, were synthesized and sent to collaborators for biological testing.